FATIGUE
Unknown
40 enrolled
CHIME
Unknown
10 enrolled
Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma
Phase 2 Unknown
27 enrolled
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
Phase 2 Unknown
50 enrolled
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Phase 1/2 Unknown
40 enrolled
Changing Over Time of Ascorbic Acid After Chemotherapy
Unknown
150 enrolled
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Phase 1 Unknown
29 enrolled
SPACE2
Unknown
150 enrolled
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Phase 2 Unknown
51 enrolled
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Phase 2 Unknown
108 enrolled
THERMAL
Unknown
20 enrolled
MALIMAR
Phase NA Unknown
50 enrolled
APA²
Phase NA Unknown
57 enrolled
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
Phase NA Unknown
18 enrolled
Place of the Hevylite Test in the Evaluation of MRD in Myeloma
Unknown
124 enrolled
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma
Phase 2 Unknown
30 enrolled
ToTem
Phase 1 Unknown
18 enrolled
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Phase 1 Unknown
10 enrolled
ProT4
Phase 2 Unknown
114 enrolled
Vascular Functions in Myeloma Patients During Anti-tumor Therapy
Unknown
96 enrolled
Cryotherapy Against Oral Mucositis After High-dose Melphalan
Phase NA Unknown
100 enrolled
BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma
Phase 1 Unknown
15 enrolled
WB-EMS and Nutrition in Patients With Hematological Malignancies
Phase NA Unknown
40 enrolled
Myeloma XI
Phase 3 Unknown
4,420 enrolled
Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma
Phase 2 Unknown
100 enrolled
Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation
Phase 2 Unknown
20 enrolled
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
Phase 1/2 Unknown
98 enrolled
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
Phase 1/2 Unknown
15 enrolled
Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment
Phase 2 Unknown
30 enrolled
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
Phase 3 Unknown
80 enrolled
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
Phase 2 Unknown
10 enrolled
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Unknown
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
Phase NA Unknown
35 enrolled
Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma
Phase 2 Unknown
60 enrolled
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
Phase 3 Unknown
750 enrolled
Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma
Phase 3 Unknown
1,000 enrolled
SU006668 in Treating Patients With Advanced Solid Tumors
Phase 1 Unknown
Beta Alethine in Treating Patients With Myeloma
Phase 1/2 Unknown
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Phase 2 Unknown
30 enrolled
Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma
Phase 3 Unknown
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Unknown
35 enrolled
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
Phase 3 Unknown
660 enrolled
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Phase 2 Unknown
80 enrolled
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
Phase 3 Unknown
450 enrolled
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
Phase 2 Unknown
100 enrolled
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Phase 3 Unknown
460 enrolled
Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Phase 1/2 Unknown
40 enrolled
Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Unknown
50 enrolled